Get the Stockscreener App
1.02
5.56%
-0.06
After Hours:
1.02
Maxcyte Inc stock is traded at $1.02, with a volume of 1.30M.
It is down -5.56% in the last 24 hours and down -17.74% over the past month.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
See More
Previous Close:
$1.08
Open:
$1.08
24h Volume:
1.30M
Relative Volume:
1.09
Market Cap:
$109.26M
Revenue:
$32.29M
Net Income/Loss:
$-39.12M
P/E Ratio:
-2.78
EPS:
-0.3669
Net Cash Flow:
$-29.51M
1W Performance:
-12.82%
1M Performance:
-17.74%
6M Performance:
-4.67%
1Y Performance:
-54.67%
1-Day Range:
$1.02
$1.095
1-Week Range:
$1.02
$1.25
52-Week Range:
$0.6434
$2.305
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.02 | 115.69M | 32.29M | -39.12M | -29.51M | -0.3669 |
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-07-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-22-25 | Initiated | Stephens | Overweight |
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
MaxCyte Inc (MXCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MaxCyte Inc (MXCT) Cash Flow - TradingKey
MXCT|MaxCyte Inc|Price:1.080|Chg%:-0.040 - TradingKey
MaxCyte Inc (MXCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MaxCyte, Inc. Revenue Breakdown – DUS:MYE0 - TradingView
MaxCyte Inc (MXCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MaxCyte Inc (MXCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Stifel Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $4 - Moomoo
MaxCyte stock surges on Genentech technology license deal By Investing.com - Investing.com South Africa
MaxCyte stock surges on Genentech technology license deal - Investing.com
MaxCyte Enters Technology License Partnership With Genentech - marketscreener.com
Genentech licenses MaxCyte cell engineering technology - Investing.com
MaxCyte licenses cell therapy tech to Genentech for research and manufacturing support - Pluang
Genentech licenses MaxCyte cell engineering technology By Investing.com - Investing.com Canada
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development - The Manila Times
Genentech Gets Access to MaxCyte Cell-Engineering Platforms - Stock Titan
MaxCyte (MXCT) Proxy filing Summary - Quartr
MaxCyte (MXCT) The 44th Annual William Blair Growth Stock Conference Summary - Quartr
MaxCyte to report Q2 2026 financial results on August 12 - scanx.trade
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026 - The Manila Times
Enterprise value to revenue forward of MaxCyte, Inc. – DUS:MYE0 - TradingView
MaxCyte(MXCT) Stock Options Chain | Quotes & News - Moomoo
Price to sales forward of MaxCyte, Inc. – DUS:MYE0 - TradingView
Price to earnings forward of MaxCyte, Inc. – DUS:MYE0 - TradingView
ETFs Investing in MaxCyte, Inc. Stocks - TradingView
MaxCyte Inc focuses on cell engineering. Nasdaq-listed MXCT targets long-term growth - Ad-hoc-news.de
MaxCyte (MXCT) Stephens Annual Investment Conference Summary - Quartr
Enterprise value to EBITDA forward of MaxCyte, Inc. – NASDAQ:MXCT - TradingView
MaxCyte stock leans on platform demand. Nasdaq listing stays central. - ad-hoc-news.de
Price to sales forward of MaxCyte, Inc. – LS:A2AGVE - TradingView
Enterprise value to revenue forward of MaxCyte, Inc. – LS:A2AGVE - TradingView
Price to book forward of MaxCyte, Inc. – NASDAQ:MXCT - TradingView
MYE0 Forecast — Price Target — Prediction for 2027 - TradingView
MaxCyte, Inc. Actuals & Estimates (NASDAQ:MXCT) - TradingView
MXCT Forecast — Price Target — Prediction for 2027 - TradingView
Craig-Hallum Maintains MaxCyte(MXCT.US) With Buy Rating - Moomoo
MaxCyte Inc (MXCT) Institutional Confidence - TradingKey
VectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering - Business Wire
Form 4 MaxCyte Inc For: 22 June By Investing.com - Investing.com South Africa
MaxCyte (MXCT) grants RSUs and stock options to director - Stock Titan
MaxCyte (MXCT) director awarded RSUs and stock options in annual grant - Stock Titan
MaxCyte (MXCT) director receives RSUs and options in annual equity grant - Stock Titan
MAXCYTE (NASDAQ: MXCT) director receives RSU and option grants as annual equity award - Stock Titan
MAXCYTE (MXCT) director Cynthia Collins receives RSUs and 49,579-share option grant - Stock Titan
MaxCyte (MXCT) director receives RSUs and 49,579 stock options in new grant - Stock Titan
MaxCyte (MXCT) director Patrick Balthrop receives RSU and stock option grants - Stock Titan
MaxCyte (MXCT) director receives RSU and stock option grant - Stock Titan
MXCT Q1 2026 Earnings: Strong EPS Beat Drives Share Price HigherOne-Time Loss Impact - dars.gov.et
Craig-Hallum Reaffirms Their Buy Rating on MaxCyte (MXCT) - The Globe and Mail
MaxCyte Stockchart levels and volatility on a quiet news day - Ad-hoc-news.de
MaxCyte, Inc. (MXCT) Announces Results of Shareholder Vote and Audit Firm Ratification – June 17, 2026 - Minichart
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
4.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):